Heat Biologics to Present at the American Association for Cancer Research (AACR) Annual Meeting
March 02, 2017 08:00 ET
|
Heat Biologics
DURHAM, N.C., March 02, 2017 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (“Heat”) (Nasdaq:HTBX), a leader in the development of immunotherapies designed to activate a patient’s immune system against...
Heat Biologics Presents Immune Data on its HS-410 Phase 2 Bladder Cancer Trial at the Genitourinary Cancers Symposium
February 17, 2017 07:00 ET
|
Heat Biologics
DURHAM, N.C., Feb. 17, 2017 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (“Heat”) (Nasdaq:HTBX), announced that it presented a poster of its immunological data from its 94-patient Phase 2 trial...
Heat Biologics to Present at the Genitourinary Cancers Symposium
February 14, 2017 08:00 ET
|
Heat Biologics
DURHAM, N.C., Feb. 14, 2017 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (“Heat”) (Nasdaq:HTBX), a leader in the development of immunotherapies designed to activate a patient’s immune system against...
Heat Biologics to Present at NobleCon13
January 24, 2017 08:00 ET
|
Heat Biologics
DURHAM, N.C., Jan. 24, 2017 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (“Heat”) (Nasdaq:HTBX), a leader in the development of immunotherapies designed to activate a patient’s immune system against...
Heat Biologics to Present at Biotech Showcase 2017 Conference in San Francisco
January 05, 2017 08:00 ET
|
Heat Biologics
DURHAM, N.C., Jan. 05, 2017 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (“Heat”) (Nasdaq:HTBX), a leader in the development of immunotherapies designed to activate a patient’s immune system against...
Heat Biologics Appoints Jeff Hutchins, Ph.D., as Chief Scientific Officer
January 04, 2017 08:00 ET
|
Heat Biologics
Industry veteran, Dr. Hutchins, to advance Heat’s platform technologies and pursue immunotherapy combinationsFormer CSO Taylor Schreiber, M.D., Ph.D., to chair Heat’s Scientific Advisory Board and...
Heat Biologics Presents Topline HS-110/Nivolumab Combination Lung Cancer Results
December 06, 2016 08:20 ET
|
Heat Biologics
Reports Positive Data on Primary Endpoint with Positive Safety Data Overall Survival Compares Favorably with Single-Agent Nivolumab Management to host a call on Thursday, December 8th, at 8:30 a.m....
Heat Biologics Presents Topline HS-410 Phase 2 Bladder Cancer Results at the Society of Urological Oncology Annual Meeting
November 30, 2016 17:27 ET
|
Heat Biologics
DURHAM, N.C., Nov. 30, 2016 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (Nasdaq:HTBX), a leader in the development of gp96-based immunotherapies that are designed to activate a patient’s immune system...
Heat Biologics to Present Topline HS-110/Nivolumab Combination Phase Ib Lung Cancer Results at the International Society for the Study of Lung Cancer Annual Meeting
November 17, 2016 07:00 ET
|
Heat Biologics
DURHAM, N.C., Nov. 17, 2016 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (Nasdaq:HTBX), a leader in the development of gp96-based immunotherapies that are designed to activate a patient’s immune system...
Heat Biologics to Present Topline HS-410 Phase II Bladder Cancer Results at the Society of Urological Oncology Annual Meeting
November 16, 2016 07:00 ET
|
Heat Biologics
DURHAM, N.C., Nov. 16, 2016 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (Nasdaq:HTBX), a leader in the development of gp96-based immunotherapies that are designed activate a patient’s immune system...